Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.
From the official U.S. FDA label for Ceflonac-SP Tablets, the active ingredient registered with NAFDAC.
Sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. Limitation of Use : Sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) ] Sodium polystyrene sulfonate for suspension is a potassium binder indicated for the treatment of hyperkalemia ( 1 ). Limitation of Use : Sodium polystyrene sulfonate for suspension should not be used an emergency treatment for life threatening hyperkalemia because of its delayed onset of action ( 1 ).
The following adverse reactions are discussed elsewhere in the labeling: Intestinal Necrosis [see Warnings and Precautions (5.1) ] Electrolyte Disturbances [see Warnings and Precautions (5.2, 5.3) ] Aspiration [see Warnings and Precautions (5.4) ] The following adverse reactions have been identified during post-approval use of sodium polystyrene sulfonate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure. …
Sodium polystyrene sulfonate is contraindicated in patients with the following conditions: Hypersensitivity to polystyrene sulfonate resins Obstructive bowel disease Neonates with reduced gut motility Hypersensitivity to polystyrene sulfonate resins ( 4 ) Obstructive bowel disease ( 4 ) Neonates with reduced gut motility ( 4 )
Intestinal Necrosis : cases of intestinal necrosis and other serious gastrointestinal events have been reported ( 5.1 ). Electrolyte Disturbances : Severe hypokalemia can occur. ( 5.2 ). Fluid overload in patient sensitive to high sodium intake : Monitor patients who are sensitive to sodium intake for signs of fluid overload. ( 5.3 ). Risk of aspiration : Acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles has been reported. ( 5.4 ). …
IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. 8.2 Lactation Risk Summary Sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. …
Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.
Ceflonac-SP Tablets contains Aceclofenac; Paracetamol; Serratiopeptidase (100 mg; 500 mg; 15 mg), as tablet, according to its NAFDAC registration record.
Yes. Ceflonac-SP Tablets is listed on the NAFDAC register under registration number B4-3760, and its registration is active as of 5 November 2026.
No WHO falsified or substandard medical product alert currently matches Ceflonac-SP Tablets in our automatically synced alert list.
Run a free authenticity scan with the NAFDAC number B4-3760, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.
Sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. Limitation of Use : Sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) ] Sodium polystyrene sulfonate for suspension is a potassium binder indicated for the treatm (Summarised from the official U.S. FDA label for Ceflonac-SP Tablets. Always follow your doctor or pharmacist.)
Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.